Home/MapLight Therapeutics/Karl Deisseroth
KD

Karl Deisseroth

Founder, Scientific Advisory Board

MapLight Therapeutics

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Schizophrenia (negative symptoms)Phase 2
ML-004Autism Spectrum Disorder (ASD)Phase 1
UndisclosedParkinson's DiseasePreclinical